On Nov 05, major Wall Street analysts update their ratings for $Krystal Biotech (KRYS.US)$, with price targets ranging from $206 to $221.
Citi analyst Yigal Nochomovitz maintains with a hold rating, and adjusts the target price from $204 to $206.
TD Cowen analyst Ritu Baral maintains with a buy rating, and maintains the target price at $208.
William Blair analyst Sami Corwin initiates coverage with a buy rating.
H.C. Wainwright analyst Joseph Pantginis maintains with a buy rating, and maintains the target price at $221.
Chardan Capital analyst Geulah Livshits maintains with a buy rating, and adjusts the target price from $208 to $212.
Furthermore, according to the comprehensive report, the opinions of $Krystal Biotech (KRYS.US)$'s main analysts recently are as follows:
Following Krystal Biotech's third-quarter earnings surpassing expectations, an analyst notes that the company's pipeline presents a significant potential upside with a series of data catalysts anticipated. These include the expected revelations for KB408-AATD and KB707-solid tumor by the end of 2024, KB407-CF in the first half of 2025, and ophthalmic B-VEC in 2025. Although these programs are currently subject to substantial risk adjustments, achieving initial proof of concept could lead to a significant reduction in perceived risks and prompt a reassessment of the investment thesis.
Here are the latest investment ratings and price targets for $Krystal Biotech (KRYS.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
